Trial Profile
A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myeloproliferative disorders; Splenomegaly; Venous thrombosis
- Focus Therapeutic Use
- Acronyms SVT-RUXO
- 13 Dec 2022 Results assessing long-term follow up (FU) of the SVT-RUXO study after a median of 104 months, range 6.2-9.8y, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 06 Nov 2019 Final long term follow up data results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Long term follow-up results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology